share_log

TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting

TScan Therapeutics To Present Updated Results From Ongoing ALLOHA Phase 1 Trial Of TSC-100 And TSC-101 At ASH Meeting

TScan治療公司將在ASH會議上展示針對TSC-100和TSC-101的ALLOHA 1期試驗的最新結果。
Benzinga ·  12/09 22:52

TSC-100 and TSC-101 are designed to treat residual disease and prevent relapse in patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning.

TSC-100和TSC-101旨在治療殘留疾病並防止急性髓性白血病(AML)、急性淋巴細胞白血病(ALL)和骨髓增生異常綜合症(MDS)患者在接受減少強度條件的異基因造血細胞移植(HCT)後復發。

The company said it is highly encouraged by the preliminary ALLOHA study results, which suggest that TSC-100 and TSC-101 have the potential to eliminate residual disease and prevent relapse in patients with AML, ALL, or MDS post-HCT.

該公司表示對初步ALLOHA研究結果感到非常鼓舞,這些結果表明TSC-100和TSC-101有潛力消除殘留疾病並防止AML、ALL或MDS患者在HCT後的復發。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 306

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。